EDUCATING THE FUTURE OF RHEUMATOLOGY AND NEPHROLOGY

GENENTECH'S FELLOWSHIP EDUCATIONAL OFFERINGS

At Genentech, we are committed to furthering the understanding of immunology. In honoring that commitment, we provide numerous educational offerings for the rheumatology and nephrology communities.

Your browser does not support the video tag.

Patients Are Our Inspiration

At Genentech, our mission is similar to that of research and teaching institutions. Making a difference in patients’ lives is and always has been our most important motivator. As a part of that commitment, we are dedicated to making sure that patients living with rheumatic diseases have access to our therapies via programs such as our Rheumatology Co-Pay Card, which covers up to $15,000/year* in co-pay assistance for eligible, commercially insured patients.1

Genentech Access Solutions

Genentech Access Solutions is a resource for effective access and reimbursement services. Over the past 20+ years, Genentech has helped more than 1.5 million patients access the Genentech medicines they need. In 2016:

Since its founding in 1976, the company’s scientists have focused drug discovery efforts on therapies that would meet serious unmet medical needs, and Genentech has brought multiple novel biotherapeutics to market.

Across the entire Genentech/Roche portfolio, we have:

13,300 employees working to solve unmet medical needs1

35 medicines on the market1

785K square feet dedicated to research1

11,300 patents received1

Invested over $10.6 billion USD in research and development (R&D) in 20162

Committed to making data accessible to medical professionals

Our R&D efforts in rheumatic diseases are focused on biomarker identification, discovery and development of best-in-class medicines, and orphan diseases. As a result, we’ve helped advance the science behind the various pathways that contribute to rheumatic diseases.

At Genentech, we respect and take seriously the guidelines that exist to govern the relationships between industry and training programs in rheumatology and nephrology. We provide a number of educational offerings that serve to fulfill our commitment to patients and the rheumatology and nephrology communities. However, it is at the discretion of the teaching institution and training program directors to determine whether these resources are consistent with your mission and needs. Available resources include:

Clinical Programs

We are committed to furthering the understanding of rheumatic diseases. We provide education that can enhance the fellows’ understanding of the immunologic basis of:

Rheumatoid arthritis

Granulomatosis with polyangiitis

Microscopic polyangiitis

Giant cell arteritis

Other topics of interest, including the latest trends in areas of interest (ie, disease assessment, clinical trial design)

Healthcare Industry Programs

We understand the importance of providing fellows with an overview of how to navigate the access and reimbursement landscape. We offer a variety of educational programs that provide the following:

An understanding of the ever-evolving healthcare environment

Practical knowledge to help clinicians navigate the current payer environment and advocate for their patients

These programs are facilitated by experts in the areas of rheumatology practice management and public policy.

Educational Resources

Rheumatologists and nephrologists are vital to achieving better patient outcomes, and we are committed to providing helpful educational resources and anatomical models.

Commitment to Professional and Patient Organizations

Each year, Genentech participates in many of the leading professional and patient conferences and meetings for rheumatology and nephrology at the national and regional levels. Additionally, we provide sponsorship for many of these conferences to encourage continued research and education in these disciplines.

Dedicated to Advancing Science to Meet Patient Needs

We have advanced the science behind approved therapies and biologics used to treat patients with a variety of autoimmune diseases. We also remain committed to studying and advancing the therapies for patients with other rheumatic diseases.